Next year marks the 20th anniversary of the first appearance of the polypill in the medical literature. Wald and Law coined the term to denote a fixed-dose combination of medications for preventing cardiovascular disease.1 They suggested that administering a polypill to all adults 55 years of age or older would reduce cardiovascular events by more than 80%. This concept generated immediate debate and a fair amount of resistance in the cardiovascular community.2 The Wald and Law proposal involved unconventional ways of thinking about who should be treated (nearly everyone) and how to deliver the therapy (with a daily combination pill). . . .
Funding and Disclosures
Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.
This editorial was published on August 26, 2022, at NEJM.org.
Print Subscriber? Activate your online access.